Search clinical trials for: CX157 (TriRima)

Total 132 results

CeNeRx BioPharma Inc.

Completed

A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)

Major Depressive Disorder

United States
CeNeRx BioPharma Inc.

Completed

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression (CX157-201)

Treatment Resistant Depression

United States
CeNeRx BioPharma Inc.

Completed

Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers (CX157-112)

Major Depressive Disorder

United States
Zimmer Biomet

Terminated

Clinical Outcomes of the Trinica(R) Anterior Lumbar Plate: Fixed Screws vs. Variable Screws

Degenerative Disc Disease | Spinal Stenosis | Spondylolisthesis

United States
University of Missouri-Columbia

Completed

Computerized Cognitive Training in Middle-Aged Adults With Generalized Anxiety Disorder: A Pilot Study (COGMA)

Generalized Anxiety Disorder

United States
University of Missouri-Columbia

Completed

Cognitive Training in Mild Cognitive Impairment (TRAIN-MCI)

Insomnia | Mild Cognitive Impairment

United States
Chimerix

Completed

A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers

Healthy

United States
TriReme Medical, LLC

Completed

Glider PTCA Balloon Catheter Registry

Coronary Disease

United Kingdom, Germany
ContraVir Pharmaceuticals, Inc.

Completed

A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

Infectious Disease

Thailand
Terumo BCT

Completed

Trima Accel® System Post Count Algorithm Study

Healthy Volunteers

United States
Terumo BCT

Completed

Evaluation of Trima Version 7.0 Platelets in 100% Plasma

Healthy Volunteers

United States
Terumo BCT

Completed

In Vivo Recovery and Survival Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution

Healthy Volunteers

United States
Universidade Federal do Rio de Janeiro
Financiadora de Estudos e Projetos; Hospital Universitario Pedro Ernesto; National... and other collaborators

Completed

Nitazoxanide Therapy for Patients With COVID-19 Pneumonia

Pneumonia, Viral | Covid19 | Corona Virus Infection

Brazil
Universidade Federal do Rio de Janeiro
National Research Council, Brazil; Ministry of Science and Technology, Brazil; ATCG... and other collaborators

Completed

Effects of Early Use of Nitazoxanide in Patients With COVID-19

Covid19 | Coronavirus

Brazil
ContraVir Pharmaceuticals, Inc.

Completed

Phase 2, Multiple Ascending Dose Proof of Concept Study

Infectious Disease

Thailand
Terumo BCT

Completed

Evaluation of Trima Version 7.0 Platelets in PAS

Healthy Volunteers

United States
Intervene Immune, Inc.

Recruiting

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial (TRIIM-X)

Immunosenescence | Epigenetic Aging

United States
Universitaire Ziekenhuizen KU Leuven
Fonds voor Wetenschappelijk Reumaonderzoek (FWRO)

Not yet recruiting

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis (RITUXERA)

Rheumatoid Arthritis

Belgium
Laida Cuevas Palomares

Recruiting

Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study

Non-Hodgkin's Lymphoma

Spain
Amsterdam UMC, location VUmc
Stichting Treatmeds

Recruiting

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS (Noisy Rebels)

Nervous System Diseases | Multiple Sclerosis | Demyelinating Autoimmune Diseases, CNS | Autoimmune Diseases of the Nervous System | Demyelinating Diseases | Multiple Sclerosis, Relapsing-Remitting

Netherlands
Byondis B.V.

Recruiting

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Lymphoma

Spain, United Kingdom, Netherlands, Italy
Sint Maartenskliniek
ZonMw: The Netherlands Organisation for Health Research and Development; Dutch...

Recruiting

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse (REDUCE-PMR-2)

Polymyalgia Rheumatica

Netherlands
Hopital Foch
Ministry of Health, France

Recruiting

Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis (RIGA)

IgA Vasculitis

France
Sint Maartenskliniek
ZonMw: The Netherlands Organisation for Health Research and Development; Dutch...

Recruiting

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed (REDUCE-PMR-1)

Polymyalgia Rheumatica

Netherlands
Christian Buske
Bayer; University of Ulm; Zentrum für Klinische Studien Ulm; X-act Cologne Clinical... and other collaborators

Active, not recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Marginal Zone Lymphoma

Germany, Austria
Azidus Brasil

Suspended

Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma (melasma)

Melasma

Brazil
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
University of Ulm
Merck Sharp & Dohme LLC; Zentrum für Klinische Studien Ulm; X-act Cologne Clinical... and other collaborators

Recruiting

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Marginal Zone Lymphoma

Austria, Germany
Kim, Seok Jin
Celltrion; Samyang Biopharmaceuticals Corporation

Recruiting

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. (Lemon-C)

Primary CNS Lymphoma

Korea, Republic of
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Primary Central Nervous System Lymphoma | Relapsed Cancer | Refractory Cancer | Recurrent Cancer

United States
International Extranodal Lymphoma Study Group (IELSG)

Not yet recruiting

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (RITZ)

Splenic Marginal Zone Lymphoma

Norway, Denmark, Sweden, Italy, Switzerland
Medical College of Wisconsin

Withdrawn

Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency

Granulomatous and Lymphocytic Interstitial Lung Disease
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada, United States, Korea, Republic of, Australia, China, Taiwan, Spain, Italy, United Kingdom, Japan, Ireland, Denmark, Hungary, Poland, Czechia, France, Israel, Singapore, Belgium, Sweden, Germany, Switzerland
Fate Therapeutics

Recruiting

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Relapsed/Refractory B-Cell Lymphoma

United States
Czech Lymphoma Study Group

Not yet recruiting

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL (CLSGMCLPOLA)

Lymphoma, Mantle-Cell

Czechia
Rachel Jones
GlaxoSmithKline; Imperial College London; University College, London; Medical Research... and other collaborators

Active, not recruiting

Rituximab and Belimumab Combination Therapy in PR3 Vasculitis (COMBIVAS)

Granulomatosis With Polyangiitis | ANCA Associated Vasculitis

United Kingdom
GlaxoSmithKline

Completed

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

Migraine Disorders

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

Poland, Turkey, Denmark, Singapore, Hungary, Hong Kong, Chile, Malaysia, Brazil, Guatemala, China, Taiwan, South Africa, Colombia, United States, Ukraine, Australia, Mexico
Fate Therapeutics

Terminated

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia

United States
Galderma R&D

Completed

Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

Melasma

United States
BeiGene

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma

United States, Italy, Spain, China, United Kingdom, Australia, Israel, Korea, Republic of, France, Brazil, Ireland, Czechia, Romania, Argentina, Puerto Rico, Austria
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Spain, Czechia, Taiwan, Italy, Japan, New Zealand, Poland, Hungary, United States, United Kingdom, Australia, Romania, Portugal, Korea, Republic of, Russian Federation, Austria, Brazil, Bulgaria, France, Ireland
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Diffuse Large B-Cell Lymphoma | DLBCL

Poland, United States, France, Israel, Italy, Turkey, Canada, Korea, Republic of, United Kingdom, Thailand, China
Won Seog Kim
Celltrion

Recruiting

[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

Primary CNS Lymphoma

Korea, Republic of
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Withdrawn

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Leukemia, Lymphocytic, Chronic, B-Cell

United States, Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
Fate Therapeutics

Withdrawn

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Lymphoma, Large B-Cell, Diffuse (DLBCL)

Italy, Canada, Israel, Korea, Republic of, Poland, Spain, Turkey
University of Washington
Bayer

Terminated

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Lymphoid Leukemia

United States
Markus Mapara
ITB-Med LLC

Recruiting

Siplizumab for Sickle Cell Disease Transplant (CD2 SCD)

Anemia, Sickle Cell

United States

Search clinical trials for: CX157 (TriRima)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations